Editorial: Emerging mutations in colorectal cancer development and progression.
作者信息
Ruff Paul
机构信息
School of Clinical Medicine, University of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa.
出版信息
Front Oncol. 2024 Aug 28;14:1469129. doi: 10.3389/fonc.2024.1469129. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Emerging mutations in colorectal cancer development and progression.社论：结直肠癌发生与进展中的新出现突变
Front Oncol. 2024 Aug 28;14:1469129. doi: 10.3389/fonc.2024.1469129. eCollection 2024.
2
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.富含高甲基化 MLH1 启动子和野生型 BRAF/KRAS 的结直肠肿瘤富含可靶向的激酶融合。
Cancer Res. 2019 Mar 15;79(6):1047-1053. doi: 10.1158/0008-5472.CAN-18-3126. Epub 2019 Jan 14.
3
Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases.原发肿瘤位置和基因组改变对结直肠腹膜转移行细胞减灭术和腹腔热灌注化疗后生存的影响。
Ann Surg Oncol. 2023 Jul;30(7):4459-4470. doi: 10.1245/s10434-023-13463-x. Epub 2023 Apr 21.
4
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency.BRAF突变是错配修复缺陷型结肠癌而非胃癌的特征。
Oncogene. 2003 Dec 11;22(57):9192-6. doi: 10.1038/sj.onc.1207061.
5
Evaluation and identification of factors related to and gene mutations in colorectal cancer: A meta-analysis.结直肠癌中与 和 基因突变相关因素的评估与鉴定：一项荟萃分析。
J Cancer Res Ther. 2016 Dec;12(Supplement):C191-C198. doi: 10.4103/0973-1482.200601.
6
BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer.BRAF 突变与晚期错配修复缺陷/微卫星高度不稳定结直肠癌的不良生存结局相关。
Oncologist. 2022 Mar 11;27(3):191-197. doi: 10.1093/oncolo/oyab055.
7
Primary Tumor Sidedness, RAS and BRAF Mutations and MSI Status as Prognostic Factors in Patients with Colorectal Liver Metastases Treated with Surgery and Thermal Ablation: Results from the Amsterdam Colorectal Liver Met Registry (AmCORE).原发性肿瘤部位、RAS和BRAF突变以及微卫星不稳定性状态作为接受手术和热消融治疗的结直肠癌肝转移患者的预后因素：来自阿姆斯特丹结直肠癌肝转移登记处（AmCORE）的结果
Biomedicines. 2021 Aug 5;9(8):962. doi: 10.3390/biomedicines9080962.
8
9
Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.转移性结直肠癌患者的游离 DNA 中出现的 RAS、BRAF 和 EGFR 突变与一线抗 EGFR 治疗的原发性和继发性耐药均相关。
Int J Clin Oncol. 2020 Aug;25(8):1523-1532. doi: 10.1007/s10147-020-01691-0. Epub 2020 May 11.
10
BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.BRAF突变分析是一种有效的工具，可用于对根据贝塞斯达指南分类的患者进行林奇综合征诊断。
Tumori. 2014 May-Jun;100(3):315-20. doi: 10.1700/1578.17214.
引用本文的文献
1
Percutaneous liver-directed therapies of intrahepatic cholangiocarcinoma.经皮肝内胆管癌的局部治疗。
Abdom Radiol (NY). 2024 Dec;49(12):4257-4263. doi: 10.1007/s00261-024-04410-9. Epub 2024 Jun 20.
本文引用的文献
1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?结直肠癌精准医学中的液体活检方法与免疫疗法：我们做到了吗？
Front Oncol. 2023 Jan 6;12:1023565. doi: 10.3389/fonc.2022.1023565. eCollection 2022.
3
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.帕博利珠单抗治疗微卫星高度不稳定型晚期结直肠癌。
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
4
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.表皮生长因子受体 S492R 突变的频率：分析接受帕尼单抗或西妥昔单抗单药治疗的转移性结直肠癌患者的血浆 DNA。
Cancer Biol Ther. 2020 Oct 2;21(10):891-898. doi: 10.1080/15384047.2020.1798695. Epub 2020 Oct 7.
5
It's contrary - comorbidity does not affect survival of South Africans with colorectal cancer: An analysis from the Colorectal Cancer in South Africa cohort.恰恰相反——合并症并不影响南非结直肠癌患者的生存：来自南非结直肠癌队列的分析。
S Afr Med J. 2020 Apr 29;110(5):382-388. doi: 10.7196/SAMJ.2020.v110i5.14252.
6
Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study.ASPECCT 研究中接受帕尼单抗治疗的转移性结直肠癌患者循环游离 DNA 中紧急突变的评估及其与临床结局的关系。
Clin Cancer Res. 2019 Feb 15;25(4):1216-1225. doi: 10.1158/1078-0432.CCR-18-2072. Epub 2018 Nov 28.
7
Design and methodology of a study on colorectal cancer in Johannesburg, South Africa.南非约翰内斯堡一项关于结直肠癌的研究的设计与方法
JGH Open. 2018 Jun 6;2(4):139-143. doi: 10.1002/jgh3.12061. eCollection 2018 Aug.
8
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.帕尼单抗联合 FOLFOX4 治疗与结直肠癌的 RAS 突变。
N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.
9
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.西妥昔单抗与化疗联合作为转移性结直肠癌的初始治疗方案
N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.
Zotero 插件